Seelos Therapeutics Inc
OTC Pink - Limited Information:SEELQ

  • LAST PRICE
    0.4950
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.3500/ 38
  • Ask / Lots
    0.5100/ 10
  • Open / Previous Close
    --- / 0.4950
  • Day Range
    ---
  • 52 Week Range
    0.2000
    698.8800
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Oct 24, 2024

      Show headlines and story abstract

    • 4:05PM ET on Thursday Oct 24, 2024 by PR Newswire
      Companies Mentioned: SEELQ

      Seelos Therapeutics, Inc. (OTCQB: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was previously postponed to Friday, October 25, 2024, from its originally scheduled date of Friday, September 27, 2024, has been further postponed. The Annual Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/SEEL2024, on Monday, November 25, 2024 at 8:00 a.m., Eastern Time. The record date for the Annual Meeting, August 19, 2024, is unchanged and applies to the postponed Annual Meeting.

    • 4:05PM ET on Thursday Oct 24, 2024 by Dow Jones
      Companies Mentioned: SEELQ

      Seelos Announces Second Postponement of its Annual Meeting of Stockholders

      PR Newswire

      NEW YORK, Oct. 24, 2024

      NEW YORK, Oct. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (OTCQB: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was previously postponed to Friday, October 25, 2024, from its originally scheduled date of Friday, September 27, 2024, has been further postponed. The Annual Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/SEEL2024, on Monday, November 25, 2024 at 8:00 a.m., Eastern Time. The record date for the Annual Meeting, August 19, 2024, is unchanged and applies to the postponed Annual Meeting.